Jan 02, 2018 8:00 am EST Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Dec 29, 2017 6:00 am EST Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Dec 28, 2017 6:30 pm EST Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
Dec 11, 2017 10:00 am EST Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)
Nov 09, 2017 8:00 am EST Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights
Nov 01, 2017 9:00 am EDT Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
Oct 26, 2017 8:00 am EDT Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection
Oct 25, 2017 8:00 am EDT Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190